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Comparative study of peritoneal 
dialysis versus hemodialysis on 
the clinical outcomes in Korea: a 
population-based approach
sung Woo Lee1, Na Rae Lee2, soo Kyung son2, Jimin Kim2, Ah Ram sul2, Yunjung Kim2, 
Jung tak park3, Jung pyo Lee  4,5 & Dong-Ryeol Ryu  6
there has been paucity of data regarding the secular trend of adverse outcomes in peritoneal dialysis 
(PD) as compared with hemodialysis (HD) in Korea. 96,596 patients who started dialysis between 
2004–2015 in Korea were identified using the National Health Insurance Service database. The adjusted 
hazard ratio (HR) (95% confidence interval, CI) of PD over HD for mortality was 1.31 (1.27–1.36; 
P < 0.001) in the period of 2004–2007 and 1.21 (1.16–1.27; P < 0.001) in the period of 2008–2011. 
However, the hazard of PD over HD for mortality turned out to be insignificant in the period of 
2012–2015. Similar trend was noted for nonfatal cardiovascular events (CVEs). In subgroup analysis, 
the hazard of pD over HD for mortality was evident, regardless of the status of age, diabetes, and 
comorbidity burden in 2004–2011. In 2012–2015, however, the hazard of PD over HD for mortality was 
insignificant when follow up was censored at one year, which became significant when follow up follow 
up was censored at three or five year. In conclusion, the mortality of PD over HD in Korea has been 
significantly improved, a finding that was paralleled by the improved nonfatal CVEs.
In Korea, the overall number of patients with end-stage renal disease (ESRD) reached 80,674 at the end of 20141. 
Among ESRD patients, 70% were on hemodialysis (HD) and 19.8% had undergone kidney transplantation. 
However, only 9.2% were on peritoneal dialysis (PD), which was attributed to the net decrease in the prevalence 
of PD patients since the mid-2000s1. The decrease of PD patients is not a unique feature of Korea. In the United 
States, the incidence of PD has decreased since the mid-1980s, while the prevalence of PD has decreased since 
the mid-1990s2. The exact reason for why the PD prevalence in Korea has decreased is not known at this time. 
However, the increased age of ESRD patients in Korea3 may have a large effect because increased age is the inde-
pendent determinant in the choice to undergo HD4. In addition, a lack of PD-related infrastructures, inadequate 
predialysis patient education, and insufficient physician training may also have had an influence on the decrease 
of PD5.
As compared with HD, PD has several advantages. First, PD is less expensive than HD6. Second, more patients 
with PD maintain their jobs compared with those using HD because of the increased schedule flexibility7. Third, 
patients with PD showed higher treatment satisfaction than did those with HD8. Fourth, patients with PD may 
have more favorable transplantation outcomes than those with HD9. Despite these advantages, however, efforts 
to revive PD have fallen into insignificance because of the lack of confidence in survival benefits of PD over HD. 
Our group recently reported that the survival rate associated with PD was inferior to that with HD among Korean 
ESRD patients who initiated dialysis between 2005 and 2008, using data from the national insurance database10. 
However, the outcomes of PD have been improved worldwide as time has gone by11–14, and Korea seems to be 
no exception15,16. Therefore, we performed the current study using a nationwide retrospective cohort to identify 
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whether the survival rate with PD has indeed been improved and to explore the secular trends of other important 
clinical outcomes of PD in Korea.
Results
We explored the baseline characteristics of the study population according to the three study periods of 2004 
to 2007, 2008 to 2011, and 2012 to 2015 (Table 1). Regardless of the study period considered, HD patients were 
older than PD patients, but the difference in age was further increased with the progression of study period. The 
proportion of medical aid was higher in HD patients than in PD patients, while income status was lower in HD 
patients than in PD patients, but this difference decreased in magnitude as the study period increased. In the 
period of 2004 to 2007, more PD patients were diabetic, but the proportion of diabetes in HD patients exceeded 
that in PD patients thereafter. In the period of 2004 to 2007, PD patients showed similar previous stroke and 
higher previous coronary artery disease (CAD) rates, respectively, but the rates of previous stroke and CAD 
seemed to be increased only in HD patients thereafter. Although the rate of atrial fibrillation was similar in PD 
patients throughout the study period, it was increased in HD patients with the progression of the study period. 
More PD patients than HD patients used statin throughout the study period, whereas more HD patients than PD 
patients used antiplatelet agents and anticoagulants throughout the study period.
We explored the crude mortality rate according to dialysis modality (Table 2). In the period of 2004 to 2007, 
the mortality rate of PD patients (105.8 per 1,000 person-years) was higher than that of HD patients (89.1 per 
1,000 person-years), which was confirmed by the finding that the hazard ratio (HR) (95% confidence interval, 
CI) of PD over HD for mortality was 1.31 (1.27–1.36; P < 0.001) in multivariate Cox proportional hazard regres-
sion analysis (Table 3). However, the mortality of PD seemed to be improved thereafter, as the hazard of PD over 
HD for mortality was not statistically significant in the period of 2012 to 2015 (HR: 1.00, 95% CI: 0.91–1.09; 
P = 0.961). We further analyzed mortality trends of dialysis modality and the respective hazard of PD over HD 
according to the year of dialysis initiation. In comparison with 2004, the hazard of mortality was significantly 
decreased in both PD and HD patients. However, the improvement was much higher in PD than in HD patients, 
which resulted in the net decrease of the hazard of mortality of PD over HD as the study period progressed and, 
ultimately, the mortality of PD presented as statistically lower than that of HD beginning in 2014 (Fig. 1).
2004–2007 (n = 32,794) 2008–2011 (n = 30,518) 2012–2015 (n = 33,329)
PD (n = 7,553) HD (n = 25,241) P PD (n = 5,968) HD (n = 24,550) P PD (n = 4,699) HD (n = 28,630) P
Age (years) 53.9 ± 13.6 55.7 ± 13.8 <0.001 54.2 ± 14.0 60.2 ± 14.0 <0.001 54.6 ± 14.1 62.5 ± 13.9 <0.001
Male sex (n, %) 4,198 (55.6) 14,649 (58.0) <0.001 3,496 (58.6) 14,511 (59.1) 0.46 2,763 (58.8) 17,285 (60.4) 0.041
Medical aid (n, %) 1,430 (18.9) 8,418 (33.4) <0.001 583 (9.8) 3,470 (14.1) <0.001 321 (6.8) 2,764 (9.7) <0.001
Income status 8.4 ± 7.1 7.0 ± 7.3 <0.001 10.3 ± 6.6 9.9 ± 7.0 <0.001 10.4 ± 6.5 10.4 ± 6.8 0.9
Diabetes (n, %) 4,093 (54.2) 11,488 (45.5) <0.001 3,486 (58.4) 1,5249 (62.1) <0.001 2,791 (59.4) 18,072 (63.1) <0.001
Hypertension (n, %) 7,344 (97.2) 19,593 (77.6) <0.001 5,915 (99.1) 2,4011 (97.8) <0.001 4,637 (98.7) 27,966 (97.7) <0.001
Previous stroke (n, %) 786 (10.4) 2,514 (10.0) 0.26 701 (11.8) 4,022 (16.4) <0.001 498 (10.6) 4,733 (16.5) <0.001
Previous CAD (n, %) 786 (10.4) 1,750 (6.9) <0.001 585 (9.8) 2,475 (10.1) 0.52 426 (9.1) 3,021 (10.6) 0.002
Malignancy (n, %) 196 (2.6) 1,340 (5.3) <0.001 195 (3.3) 1,968 (8.0) <0.001 198 (4.2) 2,610 (9.1) <0.001
Liver disease (n, %) 813 (10.76) 2,711 (10.74) 0.9 744 (12.5) 3,366 (13.7) 0.01 559 (11.9) 3,836 (13.4) 0.005
Lung disease (n, %) 665 (8.8) 2,078 (8.2) 0.12 697 (11.7) 3,204 (13.1) 0.004 562 (12.0) 4,323 (15.1) <0.001
Atrial fibrillation (n, %) 102 (1.4) 239 (1.0) 0.002 87 (1.5) 455 (1.9) 0.04 78 (1.7) 707 (2.5) 0.001
Hypothyroidism (n, %) 168 (2.2) 405 (1.6) <0.001 181 (3.0) 764 (3.1) 0.75 196 (4.2) 1,089 (3.8) 0.23
CCI score
1–3 3,506 (46.4) 13,477 (53.4) <0.001 2,366 (39.6) 7,891 (32.1) <0.001 1,929 (41.1) 9,485 (33.1) <0.001
4–6 3,545 (46.9) 9,993 (39.6) <0.001 3,066 (51.4) 13,390 (54.5) <0.001 2,358 (50.2) 15,330 (53.6) <0.001
≥7 502 (6.7) 1,771 (7.0) <0.001 536 (9.0) 3,269 (13.3) <0.001 412 (8.8) 3,815 (13.3) <0.001
ACEI/ARB (n, %) 7,186 (95.1) 22,500 (89.1) <0.001 5,649 (94.7) 22,345 (91.0) <0.001 4,173 (88.8) 23,958 (83.7) <0.001
Other anti-HTN drugs 
(n, %) 7,500 (99.3) 24,424 (96.7) <0.001 5,933 (99.4) 24,179 (98.5) <0.001 4,610 (98.1) 27,669 (96.6) <0.001
OAD (n, %) 3,183 (42.1) 9,576 (37.9) <0.001 2,470 (41.4) 10,270 (41.8) 0.53 2,007 (42.7) 12,402 (43.3) 0.44
Statin (n, %) 5,256 (69.6) 13,395 (53.1) <0.001 4,367 (73.2) 14,385 (58.6) <0.001 3,089 (65.7) 16,039 (56.0) <0.001
Anti-platelet agents 
(n, %) 5,894 (78.0) 21,985 (87.1) <0.001 4,316 (72.3) 21,126 (86.1) <0.001 2,455 (52.3) 21,435 (74.9) <0.001
Anti-coagulants (n, %) 615 (8.1) 2,524 (10.0) <0.001 400 (6.7) 2,214 (9.0) <0.001 193 (4.1) 1,897 (6.6) <0.001
Table 1. Baseline characteristics of the study population according to the study period PD, peritoneal dialysis; 
HD, hemodialysis; CAD, coronary artery disease; ACEI/ARB, angiotensinogen-converting enzyme inhibitor/
angiotensin receptor blocker; HTN, hypertension; OAD, oral antidiabetic drug; ESA, erythropoiesis-stimulating 
agent; CCI, Charlson Comorbidity Index. Values are expressed as the mean ± standard deviation for continuous 
variables and n (%) for categorical variables. Differences were evaluated by t-tests for continuous variables and 
chi-squared tests for categorical variables.
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We compared the outcomes of nonfatal cardiovascular events (CVEs) according to dialysis modality. In the 
period of 2004 to 2007, the incidence rate of nonfatal CVE (37.3 per 1,000 person-years) in PD patients was 
higher than that in HD patients (33.1 per 1,000 person-years), as shown in Table 2, which was confirmed by the 
finding that HR (95% CI) of PD over HD for nonfatal CVE was 1.15 (1.09–1.23; P < 0.001) in multivariate Cox 
proportional hazard regression analysis (Table 3). Similar to mortality, however, the outcome of nonfatal CVE in 
PD patients seemed to be improved thereafter, as the hazard of nonfatal CVE of PD over HD was not statistically 
significant in the period of 2012 to 2015 (HR: 0.92, 95% CI: 0.82–1.03; P = 0.149). Unlike in HD patients, the out-
come of nonfatal CVE in PD patients steadily improved as the study period progressed, and the hazard of nonfatal 
2004–2007 (n = 32,794) 2008–2011 (n = 30,518) 2012–2015 (n = 33,329)














Mortality 4,326 (57.3) 105.8 13,785 (54.6) 89.1 2,215 (37.1) 87.6 10,475 (42.7) 103.7 582 (12.4) 66 5,285 (18.5) 105.3
Nonfatal CVE 1,380 (18.3) 37.3 4,653 (18.4) 33.1 842 (14.1) 35.8 3,827 (15.6) 41.5 334 (7.1) 39.6 2,696 (9.4) 57.4
AMI 414 (5.5) 10.4 1,267 (5.0) 8.4 219 (3.7) 8.8 919 (3.7) 6.2 116 (1.9) 4.2 587 (2.4) 5.6
Any stroke 1,049 (13.9) 27.7 3,657 (14.5) 25.5 657 (11.0) 27.5 3,068 (12.5) 32.7 230 (4.9) 26.9 2,114 (7.4) 44.4
Ischemic stroke 242 (3.2) 6 944 (3.7) 6.2 134 (2.2) 5.4 711 (2.9) 7.2 58 (1.2) 6.6 467 (1.6) 9.4
Hemorrhagic stroke 717 (9.5) 18.4 2480 (9.8) 16.9 440 (7.4) 18.1 2,005 (8.2) 20.9 136 (2.9) 15.7 1,373 (4.8) 28.3
Table 2. Crude incidence rates of major clinical outcomes of dialysis modality according to the study period. 
PD, peritoneal dialysis; HD, hemodialysis; PY, person-year; CVE, cardiovascular event; AMI, acute myocardial 
infarction.
2004–2007 (n = 32,794) 2008–2011 (n = 30,518) 2012–2015 (n = 33,329)
Univariate Multivariate Univariate Multivariate Univariate Multivariate
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Mortality 1.18 (1.14–1.22) <0.001 1.31 (1.27–1.36) <0.001 0.84 (0.81–0.88) <0.001 1.21 (1.16–1.27) <0.001 0.63 (0.58–0.68) <0.001 1.00 (0.91–1.09) 0.9
Nonfatal CVE 1.09 (1.03–1.16) 0.003 1.15 (1.09–1.23) <0.001 0.87 (0.81–0.94) <0.001 1.10 (1.02–1.19) 0.01 0.71 (0.63–0.8) <0.001 0.92 (0.82–1.03) 0.15
AMI 1.20 (1.08–1.34) 0.001 1.28 (1.15–1.43) <0.001 0.95 (0.82–1.11) 0.54 1.23 (1.06–1.43) 0.01 1.02 (0.84–1.25) 0.81 1.33 (1.09–1.63) 0.01
Any stroke 1.06 (0.99–1.13) 0.10 1.11 (1.04–1.19) 0.003 0.85 (0.78–0.93) <0.001 1.07 (0.98–1.16) 0.13 0.62 (0.54–0.71) <0.001 0.80 (0.70–0.92) 0.002
Ischemic 0.95 (0.83–1.10) 0.50 0.97 (0.85–1.12) 0.73 0.75 (0.63–0.91) 0.003 0.83 (0.69–1.00) 0.05 0.72 (0.55–0.95) 0.02 0.74 (0.56–0.98) 0.03
Hemorrhagic 1.06 (0.98–1.16) 0.15 1.13 (1.04–1.23) 0.003 0.87 (0.79–0.97) 0.01 1.14 (1.03–1.27) 0.01 0.57 (0.48–0.68) <0.001 0.79 (0.66–0.95) 0.01
Table 3. Hazard of PD for clinical outcomes over hemodialysis according to the period. PD, peritoneal dialysis; 
HD, hemodialysis; HR, hazard ratio; CI confidence interval; CVE, cardiovascular event; AMI, acute myocardial 
infarction. In multivariate analysis, age, sex, type of insurance, income status, and CCI value were used as 
covariates.
Figure 1. Secular trend of mortality according to dialysis modality and the respective hazard of PD over HD. 
The black line indicates mortality trends of HD, while the red line indicates that of PD according to the year of 
dialysis initiation. The gray line indicates the respective hazard ratio of PD over HD. Adjusted HRs and 95% CIs 
were calculated by multivariate Cox proportional hazard regression analysis, entering age, sex, insurance type, 
income status, and CCI value as covariates. HR, hazard ratio; CI, confidence interval; HD, hemodialysis; PD, 
peritoneal dialysis.
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CVE of PD over HD presented as insignificant beginning in 2007, and was even significantly lower in year 2015 
(Fig. 2). In the details of the components of nonfatal CVE (Table 3), PD was associated with an increased hazard 
for nonfatal acute myocardial infarction (AMI) as compared with HD throughout the study period. The hazard 
of PD for nonfatal ischemic stroke was lower than that of HD for the same, a finding that was statistically insig-
nificant in the periods of 2004 to 2007 (P = 0.725) and 2008 to 2001 (P = 0.053), but which was significant in 2012 
to 2015 (P = 0.033). Although PD was associated with an increased hazard of nonfatal hemorrhagic stroke in the 
former two periods, it was associated with a decreased hazard of nonfatal hemorrhagic stroke in the period of 
2012 to 2015 as compared with HD, with a HR (95% CI) of 0.79 (0.66–0.95, P = 0.011).
We also analyzed characteristics in the crude incidence rates in the components of nonfatal CVE (Table 2). 
The crude incidence rate of nonfatal stroke was much higher than that of nonfatal AMI throughout the study 
period. Among cases of nonfatal stroke, the incidence rate of the hemorrhagic subtype was much higher than that 
of the ischemic subtype throughout the study period.
We performed subgroup analysis according to the following important effect modifiers: age, diabetes, comor-
bidity burden, and follow up duration (Fig. 3). In the period of 2004 to 2011, where the overall hazard of mortality 
of PD exceeded that of HD, the outcome of PD was consistently poorer than that of HD, regardless of the status 
of the effect modifiers. However, in the period of 2012 to 2015, the mortality of PD was comparable to that of 
HD, regardless of the status of age, diabetes, and comorbidity burden. Furthermore, although the hazard of PD 
over HD for mortality was insignificant when follow up was censored at one year, which became significant when 
follow up was censored at three or five year.
Discussion
In Korea, the prevalence of HD has steeply increased, whereas that of PD has steadily decreased as time goes 
by1. Although the exact reason for the decline of PD in Korea has not been identified, the potential hazard of PD 
over HD for mortality may partly explain the recent decrease of PD prevalence in Korea10. However, PD is more 
economical than HD because it is not only cheaper6, but also more likely to be employed than HD7. PD has a ben-
eficial effect in maintaining residual renal function17, which may more positively impact the survival rates of PD 
during the early dialysis period18 and after kidney transplantation9. According to recent registry data in Korea, the 
mortality of PD over HD seemed to be improved16, as has also been seen in other countries11–14. However, registry 
data cannot represent whole ESRD patients in Korea because not all dialysis centers nationwide participated in 
the registry. Therefore, a nationally representative study was warranted to confirm the possible improvement of 
PD mortality in Korea. With the current study, we aimed to identify secular trends of clinical outcomes in PD 
versus HD and to elucidate associated factors for the changes using a nationwide retrospective cohort of whole 
Korean ESRD patients who had begun dialysis during 2004 to 2015.
In the present study, we found that the PD patient survival became improved as the study period progressed. 
In the former two periods (years 2004–2011), PD was independently inferior to HD in terms of patient survival. 
However, the hazard of PD over HD for mortality has been nullified in the period of 2012 to 2015. In detail, the 
hazard of PD over HD for mortality was firstly insignificant in year 2013, and was significantly lower than HD in 
years 2014 to 2015. This improvement of patient survival with PD was in accordance with the results of the study 
by Mehrotra et al.12. Using the United States Renal Data System, they reported that the HR (95% CI) of PD over 
HD was 1.07 (1.04–1.11; P < 0.001) in the period of 1996 to 1998 and 1.08 (1.06–1.11; P < 0.001) in the period of 
1999 to 2001, and was ultimately nullified in the period of 2002 to 2004 (HR: 1.03, 95% CI: 0.99–1.06, P = 0.10). 
Yeates et al.13 and Chang et al.14 also reported the occurrence of early inferior but later equivocal patient survival 
rates with PD over HD among Canadian (1991–2000 vs. 2001–2004) and Taiwanese (1997–2001 vs. 2002–2006) 
patients. The increased prescription of solutions with low-glucose degradation products and neutral pHs along 
Figure 2. Secular trend of nonfatal CVE according to dialysis modality and the respective hazard of PD over 
HD. The black line indicates nonfatal CVE trends of HD, and the red line indicates that of PD according to 
the year of dialysis initiation. The gray line indicates the respective hazard ratio of PD over HD. Adjusted HRs 
and 95% CIs were calculated by multivariate Cox proportional hazard regression analysis, entering age, sex, 
insurance type, income status, and CCI value as covariates. HR, hazard ratio; CI, confidence interval; HD, 
hemodialysis; PD, peritoneal dialysis; CVE, cardiovascular event.
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with improved technique survival and peritonitis outcomes may have led to the improvement of PD patient sur-
vival in Korea19,20.
In the current study, the outcome of nonfatal CVE in PD was significantly poorer than that in HD in the 
former two periods (years 2004–2011). However, the hazard of nonfatal CVE with PD over HD became insig-
nificant in 2012 to 2015, an occurrence that was largely attributed to the significantly lower hazard of nonfatal 
CVE with PD over HD in 2015. The trend of hazard with PD over HD for nonfatal CVE was mostly paralleled 
by that of nonfatal stroke, particularly the hemorrhagic subtype (Fig S1). In the general Korean population, the 
incidence of nonfatal stroke was higher than that of nonfatal AMI21, which was also true in the current study’s 
ESRD cohort. However, although the majority of nonfatal stroke cases involved the ischemic subtype in the gen-
eral population21, the major subtype of nonfatal stroke in the present ESRD cohort was hemorrhagic, which was 
quite a unique feature to see in Korean ESRD patients22. Therefore, we postulated that the improved PD patient 
survival in this study may also be affected by the improved outcome of nonfatal hemorrhagic stroke, a major sub-
type of nonfatal stroke. The increased rates of atrial fibrillation and previous stroke in HD patients as well as the 
decreased use of antiplatelet agents and anticoagulants in PD patients may have impacted the nonhemorrhagic 
stroke rate.
Although the current study did not clearly demonstrate so, generally, young, nondiabetic patients with low 
comorbidity burdens are thought to be good candidates for PD2. Nevertheless, Korean ESRD patients with previ-
ous myocardial infarction, diabetes, and congestive heart failure tended to choose PD, which leads to an increased 
mortality risk4. In this study, more PD patients had diabetes and previous CAD than did HD patients in the 
period of 2004 to 2007. However, the rates of diabetes and previous CAD in HD patients increased thereafter. 
This improved risk profile led the reduced risk of nonfatal AMI development in PD patients throughout the study 
period. Since the increased risk of nonfatal AMI development throughout the study period was a major short-
coming of PD in this study, the good control of risk profiles and the resultant improvement of nonfatal AMI in PD 
patients may also affect the survival of these individuals.
This study has several limitations. First, the study was retrospective in nature, which limits the causal relation-
ship. However, the study cohort was nationally representative and included all incident ESRD patients. Therefore, 
this limitation may be partially compensated for. Second, claims data can under- or overreport the true value. 
However, such misclassification may have an impact equally throughout the study period. Therefore, this weak-
ness may ultimately have little effect on the study results. Third, the evaluation of a single nation with a single 
ethnicity may limit the generalizability of the present study to other parts of the world.
Figure 3. Subgroup analysis of the association between dialysis modality and patient mortality. Adjusted 
HRs and CIs were calculated by multivariate Cox proportional hazard regression analysis, entering age, 
sex, insurance type, income status, and CCI as covariates. HR, hazard ratio; CI, confidence interval; HD, 
hemodialysis; PD, peritoneal dialysis; Charlson Comorbidity Index, CCI; FU, follow up.
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In conclusion, similar to other countries, PD patient survival in Korea has been significantly improved and 
the hazard of mortality of PD was significantly lower than that of HD during recent years. Improved outcomes of 
nonfatal CVE, particularly the hemorrhagic stroke subtype, may lead to further improvement.
Methods
source of data. The National Health Insurance Service database (NHIS; Seoul, South Korea)—a public data-
base related to health care utilization, health screening, sociodemographic variables, and mortality of the whole 
population of Korea—was used23. The NHIS database contains information pertaining to demographics and 
all the medical services rendered, along with the relevant diagnostic code(s) (as per the International Statistical 
Classification of Diseases and Related Health Problems, 10th edition (ICD-10) code) and all dispensed prescrip-
tion medications.
study design. A nationwide retrospective cohort study based on the NHIS database was conducted. The 
source population included all of the patients with ESRD who underwent initial dialysis for at least two months 
between January 1, 2004 and December 31, 2015.
An eligible cohort of new patients treated with dialysis was identified among individuals who were dialyzed 
for two months or longer between January 1, 2004 and December 31, 2015. The date of the first dialysis was con-
sidered to be the initiation date. Individuals who had a claim for dialysis before the initiation date, who under-
went renal transplantation before the initiation date or within three months after the initiation date, who died or 
were lost to follow-up within three months of the initiation date, and/or those who were not dialyzed within three 
months after the initiation date were excluded from the present study.
Eligible individuals were monitored until the diagnosis of cardiovascular disease, death, or kidney transplan-
tation and followed until December 31, 2015. The protocol of the present study was approved by the ethics review 
committee of the National Evidence-based Healthcare Collaborating Agency (institutional review board num-
ber: NECA IRB 16–007–1). The study protocol adhered to the principles of the Declaration of Helsinki. Written 
informed consent was waived as the study did not infringe on patient privacy or health status.
Case definition. Within the eligible cohort, we identified cases that claimed HD (V003, O7020, O9991) at 
three months after the initiation date of dialysis. The rationale for designating case definition at three months was 
to include patients who were finally treated with PD, even though they were usually treated initially by temporary 
HD. Therefore, patients who were treated with both HD and PD were identified as PD cases.
Definitions and measurements. The comorbidities of interest were diabetes, hypertension, previous 
stroke, previous CAD, malignancy, liver and lung disease, atrial fibrillation, and hypothyroidism, which were 
chosen on the basis of suggestions by Charlson et al.24 to calculate the Charlson Comorbidity Index (CCI). These 
comorbidities were defined using ICD-10 codes according to the proposed algorithms of Quan et al.25 over a 
one-year period prior to initiation of dialysis therapy. Prescribed medications of interest were angiotensin II 
receptor blocker/angiotensin-converting enzyme inhibitors, other antihypertensive drugs, oral antidiabetic 
drugs, statin, antiplatelet agents, erythropoiesis-stimulating agents, and supplemental vitamin D. All medication 
users were defined as individuals who were prescribed medication at least once during the follow-up period after 
the index date of dialysis. Income status was classified into 20 classes according to the level of insurance premium; 
for reference, Level 1 denotes the bottom 5%, while level 20 denotes the top 5%.
The primary outcome of the current study was mortality, and secondary outcomes were nonfatal CVEs. 
Mortality was ascertained using data of the Korea National Statistical Office for the cause of death, after exclud-
ing deaths due to aging, Parkinson’s disease, suicide, and accidents. Nonfatal CVEs included nonfatal AMI and 
stroke, which were defined as the first hospitalization with I21-I22 code or I60-I68 code, respectively, after dialysis 
initiation that did not end in death.
statistical analysis. Continuous variables are expressed as the mean ± standard deviation and categorical 
variables are expressed as the percentage. Differences were analyzed using the Student’s t-test for continuous var-
iables and the chi-squared test for categorical variables. HRs and 95% CIs of PD over HD for mortality and non-
fatal CVEs were calculated using a Cox proportional hazards regression model. The assumption of proportional 
hazard was tested by log-minus-log plot for categorical variables and interaction analysis with time covariate 
using time-dependent Cox regression for continuous variables. In multivariate analysis, age, sex, type of insur-
ance, income status, and CCI were used as covariates. Death was treated as censoring when we calculated the 
hazard of nonfatal CVEs. A P-value of less than 0.05 was considered to be statistically significant, and all statistical 
analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).
Data Availability
Available as supplementary material when accepted
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